ceritinib

Pre-clinicalActive

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Anaplastic Lymphoma Kinase (ALK)- Positive Tumors

Conditions

Anaplastic Lymphoma Kinase (ALK)- Positive Tumors, Non-small Cell Lung Cancer (NSCLC)

Trial Timeline

— → —

NCT ID

NCT05100134

About ceritinib

ceritinib is a pre-clinical stage product being developed by Novartis for Anaplastic Lymphoma Kinase (ALK)- Positive Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT05100134. Target conditions include Anaplastic Lymphoma Kinase (ALK)- Positive Tumors, Non-small Cell Lung Cancer (NSCLC).

What happened to similar drugs?

0 of 1 similar drugs in Anaplastic Lymphoma Kinase (ALK)- Positive Tumors were approved

Approved (0) Terminated (0) Active (1)

🔄Alectinib + CrizotinibRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05100134	Pre-clinical	Active	—	—	Anaplastic Lymphoma Kinase (ALK)- Positive Tumors
NCT02584933	Approved	Active	Dec 11, 2015	Jun 9, 2027	ALK Positive Malignancies
NCT02638909	Phase 2	Terminated	Dec 1, 2015	Mar 29, 2018	Colorectal Adenocarcinoma
NCT02513667	Phase 2	Terminated	Nov 1, 2015	May 29, 2021	ALK-positive Non-small Cell Lung Cancer
NCT02289144	Phase 2	Withdrawn	Jun 1, 2015	Jan 1, 2019	Metastatic Anaplastic Thyroid Cancer
NCT02343679	Phase 2	Withdrawn	May 1, 2015	Oct 1, 2022	Hematologic Malignancies
NCT02299505	Phase 1	Completed	Apr 9, 2015	Mar 6, 2020	Non-Small Cell Lung Cancer
NCT02336451	Phase 2	Completed	Apr 1, 2015	Feb 6, 2019	ALK-positive Non-small Cell Lung Cancer
NCT02186821	Phase 2	Terminated	Sep 17, 2014	Dec 13, 2017	Tumors With Aberrations in ALK or ROS1
NCT01742286	Phase 1	Completed	Aug 28, 2013	Apr 26, 2019	ALK-activated Tumors

Competing Products

20 competing products in Anaplastic Lymphoma Kinase (ALK)- Positive Tumors

See all competitors

Product	Company	Stage	Hype Score
CS-7017 + Paclitaxel	Daiichi Sankyo	Phase 1/2	24
efatutazone + paclitaxel	Daiichi Sankyo	Phase 2	35
Lenvatinib 24 mg	Eisai	Phase 2	27
Lenvatinib + Nivolumab	Ono Pharmaceutical	Phase 2	39
durvalumab + tremelimumab	AstraZeneca	Phase 1	29
Pembrolizumab	Merck	Phase 2	35
LDK378 + AUY922	Novartis	Phase 1	29
LDK378	Novartis	Phase 1	29
Ceritinib	Novartis	Phase 2	27
Gemcitabine + ribociclib + sonidegib + trametinib + filgrastim	Novartis	Phase 1	29
dabrafenib/trametinib	Novartis	Phase 2	42
Trametinib + Paclitaxel	Novartis	Phase 1	33
Alectinib + Crizotinib	Roche	Phase 3	44
Sunitinib Malate	Pfizer	Phase 2	35
Crizotinib (PF-02341066)	Pfizer	Phase 2	35
Lorlatinib	Pfizer	Phase 2	31
Crizotinib	Pfizer	Phase 1/2	32
Cemiplimab + XL092	Regeneron Pharmaceuticals	Phase 1	36
Etirinotecan pegol	Nektar Therapeutics	Phase 2	29
Bevacizumab	Novocure	Phase 2	36